{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T07:59:14Z","timestamp":1761292754650},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1007\/s12094-010-0579-4","type":"journal-article","created":{"date-parts":[[2010,10,26]],"date-time":"2010-10-26T08:10:54Z","timestamp":1288080654000},"page":"692-700","source":"Crossref","is-referenced-by-count":14,"title":["Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain"],"prefix":"10.1007","volume":"12","author":[{"given":"Carmen","family":"Fr\u00edas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel \u00c1ngel","family":"Segu\u00ed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itziar","family":"Oyag\u00fcez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel \u00c1ngel","family":"Casado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,10,27]]},"reference":[{"key":"579_CR1","unstructured":"Ministerio de Sanidad y Consumo (2005) La situaci\u00f3n del c\u00e1ncer en Espa\u00f1a. Available at http:\/\/www.msc.es\/ciudadanos\/enfLesiones\/enf-NoTransmisibles\/docs\/situacionCancer.pdf"},{"issue":"Suppl1","key":"579_CR2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0025-7753(08)76433-9","volume":"131","author":"A. Izquierdo","year":"2008","unstructured":"Izquierdo A, Gispert R, Saladie F, Espin\u00e0s JA (2008) An\u00e1lisis de la incidencia, la supervivencia y la mortalidad seg\u00dan las principales localizaciones tumorales, 1985\u20132019: c\u00e1ncer de mama. Med Clin (Barc) 131(Suppl 1):50\u201352","journal-title":"Med Clin (Barc)"},{"key":"579_CR3","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s12094-006-0051-7","volume":"8","author":"M. Mart\u00edn","year":"2006","unstructured":"Mart\u00edn M, Mahillo E, Llombart-Cussac A et al (2006) The \u201cEl Alamo\u201d project (1990\u20131997): two consecutive hospital-based studies of breast cancer outcomes in Spain. Clin Transl Oncol 8:508\u2013518","journal-title":"Clin Transl Oncol"},{"key":"579_CR4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/sj.bjc.6601890","volume":"91","author":"E. Rem\u00e1k","year":"2004","unstructured":"Rem\u00e1k E, Brazil L (2004) Cost of managing women presenting with stage IV breast cancer in the United Kingdom. Br J Cancer 91:77\u201383","journal-title":"Br J Cancer"},{"key":"579_CR5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1130-6343(08)72832-0","volume":"32","author":"Grupo Espa\u00f1ol para el Desarrollo de la Farmacia Oncol\u00f3gica","year":"2008","unstructured":"Grupo Espa\u00f1ol para el Desarrollo de la Farmacia Oncol\u00f3gica (GEDEFO) (2008) Estudio transversal del tratamiento del c\u00e1ncer de mama en Espa\u00f1a. Farm Hosp 32:139\u2013147","journal-title":"Farm Hosp"},{"issue":"2Suppl.7","key":"579_CR6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0093-7754(01)90273-8","volume":"28","author":"P. Conte","year":"2001","unstructured":"Conte P, Salvadori B, Donati S et al (2001) Gemcitabine, epirubicin, and paclitaxel combinations in advanced breast cancer. Semin Oncol 28(2 Suppl. 7):15\u201317","journal-title":"Semin Oncol"},{"issue":"Suppl3","key":"579_CR7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1634\/theoncologist.10-90003-20","volume":"10","author":"J. O\u2019shaughnessy","year":"2005","unstructured":"O\u2019shaughnessy J (2005) Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10(Suppl 3):20\u201329","journal-title":"Oncologist"},{"key":"579_CR8","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/CAD.0b013e3280bad81a","volume":"18","author":"L.G. Estevez","year":"2007","unstructured":"Estevez LG, Tusquets I, Mu\u00f1oz M et al (2007) Advanced breast cancer: chemotherapy phase III trials that change a standard. Anticancer Drugs 18:843\u2013859","journal-title":"Anticancer Drugs"},{"key":"579_CR9","first-page":"614","volume":"22","author":"M.J. Higgins","year":"2008","unstructured":"Higgins MJ, Wolff AC (2008) Therapeutic options in the management of metastatic breast cancer. Oncology (Williston Park) 22:614\u2013623","journal-title":"Oncology (Williston Park)"},{"issue":"2","key":"579_CR10","first-page":"CD003366","volume":"18","author":"D. Ghersi","year":"2005","unstructured":"Ghersi D, Wilcken N, Simes J, Donoghue E (2005) Taxane containing regimens for metastatic breast cancer. Cochrane Database Syst Rev Apr 18;2:CD003366","journal-title":"Cochrane Database Syst Rev Apr"},{"key":"579_CR11","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.2165\/00003495-200565170-00007","volume":"65","author":"K.A. Lyseng-Williamson","year":"2005","unstructured":"Lyseng-Williamson KA, Fenton C (2005) Docetaxel: a review of its use in metastatic breast cancer. Drugs 65:2513\u20132531","journal-title":"Drugs"},{"key":"579_CR12","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2165\/00003495-200059030-00015","volume":"59","author":"D.P. Figgitt","year":"2000","unstructured":"Figgitt DP, Wiseman LR (2000) Docetaxel. An update of its use in advanced breast cancer. Drugs 59:621\u2013651","journal-title":"Drugs"},{"key":"579_CR13","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.2165\/00019053-200119110-00003","volume":"19","author":"R.E. Brown","year":"2001","unstructured":"Brown RE, Hutton J, Burrell A (2001) Cost-effectiveness of treatment options in advanced breast cancer in the UK. Pharmacoeconomics 19:1091\u20131102","journal-title":"Pharmacoeconomics"},{"key":"579_CR14","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1200\/JCO.2001.19.22.4216","volume":"19","author":"E.A. Perez","year":"2001","unstructured":"Perez EA, Vogel CL, Irwin DH et al (2001) Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19:4216\u20134223","journal-title":"J Clin Oncol"},{"key":"579_CR15","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1634\/theoncologist.10-9-665","volume":"10","author":"A. Eniu","year":"2005","unstructured":"Eniu A, Palmieri FM, Perez EA (2005) Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist 10:665\u2013685","journal-title":"Oncologist"},{"key":"579_CR16","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa0707056","volume":"358","author":"J.A. Sparano","year":"2008","unstructured":"Sparano JA, Wang M, Martino S et al (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663\u20131671","journal-title":"N Engl J Med"},{"key":"579_CR17","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3816\/CBC.2008.n.025","volume":"8","author":"S.E. Jones","year":"2008","unstructured":"Jones SE (2008) Metastatic breast cancer: the treatment challenge. Clin Breast Cancer 8:224\u2013233","journal-title":"Clin Breast Cancer"},{"key":"579_CR18","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1517\/14656566.9.15.2603","volume":"9","author":"E. Saloustros","year":"2008","unstructured":"Saloustros E, Mavroudis D, Georgoulias V (2008) Paclitaxel and docetaxel in the treatment of breast cancer. Expert Opin Pharmacother 9:2603\u20132616","journal-title":"Expert Opin Pharmacother"},{"key":"579_CR19","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.ejca.2008.07.019","volume":"44","author":"N. Wilcken","year":"2008","unstructured":"Wilcken N, Dear R (2008) Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000\u20132007. Eur J Cancer 44:2218\u20132225","journal-title":"Eur J Cancer"},{"key":"579_CR20","doi-asserted-by":"crossref","first-page":"5542","DOI":"10.1200\/JCO.2005.02.027","volume":"23","author":"S.E. Jones","year":"2005","unstructured":"Jones SE, Erban J, Overmoyer B, et al (2005) Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23:5542\u20135551","journal-title":"J Clin Oncol"},{"key":"579_CR21","doi-asserted-by":"crossref","unstructured":"Jones SE, Benedict A, Cameron D, Jourdan S (2007) Cost-effectiveness of docetaxel compared to paclitaxel in metastatic breast cancer: A UK health economic analysis. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 25, 18S (June 20 Supplement):1081","DOI":"10.1200\/jco.2007.25.18_suppl.1081"},{"key":"579_CR22","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/annonc\/mdm527","volume":"19","author":"T. Vu","year":"2008","unstructured":"Vu T, Ellard S, Speers CH et al (2008) Survival outcome and cost-effectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: a population-based evaluation. Ann Oncol 19:461\u2013464","journal-title":"Ann Oncol"},{"key":"579_CR23","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1517\/14656560802653206","volume":"10","author":"Z. Lwin","year":"2009","unstructured":"Lwin Z. Leighl N (2009) Economic evaluation of docetaxel for breast cancer. Expert Opin Pharmacother 10:283\u2013290","journal-title":"Expert Opin Pharmacother"},{"key":"579_CR24","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2165\/10899510-000000000-00000","volume":"27","author":"A. Benedict","year":"2009","unstructured":"Benedict A, Cameron DA, Corson H, Jones SE (2009) An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK. Pharmacoeconomics 27:847\u201359","journal-title":"Pharmacoeconomics"},{"key":"579_CR25","doi-asserted-by":"crossref","DOI":"10.1002\/0471458546","volume-title":"Statistical methods for survival data analysis","author":"E. Lee","year":"2003","unstructured":"Lee E, Wang JW (2003) Statistical methods for survival data analysis, 3rd edn. Wiley Interscience, Indianapolis","edition":"3rd edn."},{"key":"579_CR26","unstructured":"Verrill MW, Lee J, Cameron DA for the Anglo-Celtic IV trial (2007) First results of a UK National Cancer Research Network randomised phase 3 pharmacogenetic trial of weekly versus 3 weekly Paclitaxel in patients with locally advanced or metastatic breast cancer (ABC) J Clin Oncol. ASCO Annual Meeting Proceedings Part I. 25:LBA1005"},{"key":"579_CR27","volume-title":"Propuesta de gu\u00eda para la evaluaci\u00f3n econ\u00f3mica aplicada a las tecnolog\u00edas sanitarias","author":"J. L\u00f3pez Bastida","year":"2008","unstructured":"L\u00f3pez Bastida J, Oliva J, Anto\u00f1anzas F et al (2008) Propuesta de gu\u00eda para la evaluaci\u00f3n econ\u00f3mica aplicada a las tecnolog\u00edas sanitarias. Madrid: Plan Nacional para el SNS del MSC. Servicio de Evaluaci\u00f3n del Servicio Canario de la Salud; Informes de Evaluaci\u00f3n de Tecnolog\u00edas Sanitarias: SESCS No 2006\/22. Available at http:\/\/aunets.isciii.es\/ficherosproductos\/132\/MemoriaFinal.pdf"},{"key":"579_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3020","volume":"3","author":"A.H. Briggs","year":"1999","unstructured":"Briggs AH, Gray AM (1999) Handling uncertainty when performing economic evaluation of healthcare interventions. Health Technol Assess 3:1\u2013134","journal-title":"Health Technol Assess"},{"key":"579_CR29","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/sj.bjc.6603326","volume":"95","author":"A. Lloyd","year":"2006","unstructured":"Lloyd A, Nafees B, Narewska J (2006) Health state utilities for metastatic breast cancer. Br J Cancer 95:683\u2013690","journal-title":"Br J Cancer"},{"key":"579_CR30","unstructured":"IMS Health. MIDAS, MAT. Dec 2009 [database]"},{"key":"579_CR31","unstructured":"Oblikue Consulting (2009). Base de datos sanitarios e-Salud Available at http:\/\/www.oblikue.com\/bddcostes\/ ."},{"key":"579_CR32","unstructured":"Consejo General de Colegios de Farmac\u00e9uticos 2009 Cat\u00e1logo de Medicamentos. Consejo Plus. Madrid. Available at http:\/\/www.portalfarma.com"},{"key":"579_CR33","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2165\/00019053-199813040-00003","volume":"13","author":"A. Briggs","year":"1998","unstructured":"Briggs A, Sculpher M (1998) An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 13:397\u2013409","journal-title":"Pharmacoeconomics"},{"key":"579_CR34","first-page":"231","volume":"28","author":"J.M. Rodriguez Barrios","year":"2004","unstructured":"Rodriguez Barrios JM (2004) Papel de los modelos en las evaluaciones econ\u00f3micas en el campo sanitario. Farm Hosp 28:231\u2013242","journal-title":"Farm Hosp"},{"key":"579_CR35","doi-asserted-by":"crossref","unstructured":"Drummond MF, Sculpher MJ, Torrance BJ et al (2005) Methods for the economic evaluation of health care programmes, 3rd edn. Oxford University Press","DOI":"10.1093\/oso\/9780198529446.001.0001"},{"key":"579_CR36","doi-asserted-by":"crossref","first-page":"752","DOI":"10.7326\/0003-4819-127-8_Part_2-199710151-00063","volume":"127","author":"X.H. Zhou","year":"1997","unstructured":"Zhou XH, Melfi CA, Hui SL (1997) Methods for comparison of cost data. Ann Intern Med 127:752\u2013756","journal-title":"Ann Intern Med"},{"key":"579_CR37","unstructured":"Briggs A, Goeree R, Blackhouse G, O\u2019Brien B (2001) Probabilistic analysis of cost-effectiveness models: Choosing between treatment strategies for gastro-esophageal reflux disease. McMaster University Centre for Heatlh Economics and Policy Analysis Research Working Paper 01-01"},{"key":"579_CR38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1524-4733.2005.08101.x","volume":"8","author":"A. Briggs","year":"2005","unstructured":"Briggs A (2005) Probabilistic analysis of costeffectiveness models: statistical representation of parameter uncertainty. Value Health 8:1\u20132","journal-title":"Value Health"},{"key":"579_CR39","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0213-9111(02)71933-X","volume":"16","author":"J.A. Sacrist\u00e1n","year":"2002","unstructured":"Sacrist\u00e1n JA, Oliva J, Del Llano J, Prieto L, Pinto JL (2002) \u00bfQu\u00e9 es una tecnolog\u00eda sanitaria eficiente en Espa\u00f1a? Gac San 16:334\u2013343","journal-title":"Gac San"},{"key":"579_CR40","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2165\/00019053-199600092-00004","volume":"9","author":"J. Hutton","year":"1996","unstructured":"Hutton J, Brown R, Borowitz M et al (1996) A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. Pharmacoeconomics 9:8\u201322","journal-title":"Pharmacoeconomics"},{"key":"579_CR41","doi-asserted-by":"crossref","first-page":"504","DOI":"10.2165\/00019053-199610050-00008","volume":"10","author":"R. Launois","year":"1996","unstructured":"Launois R, Reboul-Marty J, Henry B, Bonneterre J (1996) A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine. Pharmacoeconomics 10:504\u2013521","journal-title":"Pharmacoeconomics"},{"issue":"Suppl2","key":"579_CR42","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1093\/ajhp\/54.suppl_2.S11","volume":"54","author":"G.C. Yee","year":"1997","unstructured":"Yee GC (1997) Cost-utility analysis of taxane therapy. Am J Health-Syst Pharm 54(Suppl 2): S11\u2013S15","journal-title":"Am J Health-Syst Pharm"},{"key":"579_CR43","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2165\/00019053-199814040-00010","volume":"14","author":"H.M. Lamb","year":"1998","unstructured":"Lamb HM, Wiseman LR (1998) Docetaxel. A pharmacoeconomic review of its use in the treatment of metastatic breast cancer. Pharmacoeconomics 14:447\u2013459","journal-title":"Pharmacoeconomics"},{"key":"579_CR44","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/00001813-199811000-00009","volume":"9","author":"R.E. Brown","year":"1998","unstructured":"Brown RE, Hutton J (1998) Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients. Anti-Cancer Drugs 9:899\u2013907","journal-title":"Anti-Cancer Drugs"},{"key":"579_CR45","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12094-009-0309-y","volume":"11","author":"M. Martin-Jimenez","year":"2009","unstructured":"Martin-Jimenez M, Rodriguez-Lescure A, Ruiz-Borrego M (2009) Cost effectiveness analysis of docetaxel (Taxotere) vs. 5-fluorouracil in combined therapy in the initial phases of breast cancer. Clin Transl Oncol 11:41\u201347","journal-title":"Clin Transl Oncol"},{"key":"579_CR46","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1524-4733.2007.00186.x","volume":"10","author":"L.P. Garrison Jr","year":"2007","unstructured":"Garrison LP Jr, Neumann PJ, Erickson P et al (2007) Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health 10:326\u2013335","journal-title":"Value Health"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-010-0579-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-010-0579-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-010-0579-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T20:23:25Z","timestamp":1711916605000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-010-0579-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["579"],"URL":"https:\/\/doi.org\/10.1007\/s12094-010-0579-4","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}